Hikma Pharmaceuticals: Seizures trials

The registry lists 10 Seizures studies with Hikma Pharmaceuticals as lead sponsor. 0 are open to participants now and 0 have results posted.

Phase 1 2Phase 3 1No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed ConditionsCompletedNCT01703468Phase 1
• Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fasted ConditionsCompletedNCT01702623Phase 1
• Evaluation Phenobarbital as Adjunctive Therapy in Participants With Partial Onset SeizuresCompletedNCT01284556Phase 3
• Bioequivalency Study of Levetiracetam 1g Tablets Under Fed ConditionsCompletedNCT00827320Not applicable
• Bioequivalency Study of Levetiracetam 750 mg Tablets Under Fasting ConditionsCompletedNCT00826865Not applicable
• Bioequivalency Study of Levetiracetam 750 mg Tablets Under Fed ConditionsCompletedNCT00826787Not applicable
• Bioequivalency Study of Levetiracetam 1g Under Fasted ConditionsCompletedNCT00826722Not applicable
• Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed ConditionsCompletedNCT00618046Not applicable
• Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed ConditionsCompletedNCT00616863Not applicable
• Bioequivalency Study of 600 mg Oxcarbazepine Tablets Under Fasting ConditionsCompletedNCT00616681Not applicable